Clinical Trials
48 trialsEXCEED
Eli Lilly and Company
NEXUS-01
Eli Lilly and Company
FORAGER-1
Eli Lilly and Company
EV-309
Astellas Pharma Inc
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
EV-103
Astellas Pharma Inc
BOOST
Relmada Therapeutics, Inc.
RESCUE
Relmada Therapeutics, Inc.
RESCUE
Relmada Therapeutics, Inc.
SURF301
Tyra Biosciences, Inc
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
CG Oncology, Inc.
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen Inc.
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
PAVO
Tempus AI
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology LLC
Meteor 1
GlaxoSmithKline
EV-201
Astellas Pharma Inc
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Hoffmann-La Roche
JAVELIN Bladder 100
Pfizer
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies
AO GENERIUM
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Aravive, Inc.
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
NanOlogy, LLC
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
LUX-Bladder 1
Boehringer Ingelheim
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Celldex Therapeutics
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Celldex Therapeutics
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
EMBARC-RF
Bioniche Life Sciences Inc.
OPTIMA
UroGen Pharma Ltd.
Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
UroGen Pharma Ltd.
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
Achieve Life Sciences
Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients
UroGen Pharma Ltd.
JASINT1
Pierre Fabre Medicament
NMIBC TURBT HG
UroGen Pharma Ltd.
SHTC-EUROPE-1
Medical Enterprises Europe B.V.
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Merck Sharp & Dohme LLC
A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer
Hoffmann-La Roche
Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer
Medical Enterprises Europe B.V.
A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer
Hoffmann-La Roche
Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)
Eli Lilly and Company
Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium
Achieve Life Sciences
2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
Eli Lilly and Company
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
Pharmacyclics LLC.
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
GammaCan
A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Eli Lilly and Company
A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
Eli Lilly and Company